Fierce's Top 10 Biotech Techies - 2013
Jam "biotech" and "techie" together, and you get a term that might be twice as tricky to understand as either of those two words alone.Read the profiles in our second annual "Top 10 Biotech Techies" report (find last year's list here) and you'll see what this term means to us--people who combine the best of high technology and biotechnology to solve major problems in healthcare.
The 10 people featured in this report have huge healthcare problems in their crosshairs, using IT as a central component to their potential solutions.
The 25 most influential people in biopharma today - 2013
Influence is a fungible asset.A lot of cash on hand can help tremendously, of course. But at this stage, who in this business hasn't seen billions incinerated in pursuit of sheer folly? Far more influential is the savvy executive who can marshal experts as well as financial resources in pursuit of a smarter, better, faster way to develop and market important new drugs.
And intelligent research strategies are far more rare than we acknowledge.
You'll find some here in our second annual report on the 25 most influential people in the industry. Read the report >>
Top 50 Industry Voices in Biotech Twittersphere -- 2012
FierceBiotech has been working with Appeering, which tracks industry dialogues on Twitter, since this summer to feature interesting conversations with our readers. Appeering has its own special algorithm for rating individuals that is based on the ratio of how many people they follow versus how many follow them; how well Twitter users' content is shared by others; and the real conversations people have with industry counterparts on the site.There are a lot of reasons to build a Twitter audience, and one great reason is to establish your own personal brand that you can carry with you no matter where you work.
Q3 biotech venture investing makes a boisterous leap
The life sciences industry gained a blast of good news on the venture front today. The National Venture Capital Association and PricewaterhouseCoopers outlined a buoyant set of numbers for the industry, noting a nice spike in the amount invested in biotechs as well as the number of deals completed.Using the figures provided by Thomson Reuters, the quarterly report concluded that total life sciences venture deals topped $1.7 billion in 181 deals in the third quarter--a bit more than a quarter of all investments tracked during the period. Excluding medical devices, biotech gained $1.2 billion of that for 116 companies, a hefty 64% increase in dollars and a 22% jump in deals.
That rate was even better than the same period last year, when biotech garnered $1.1 billion for 96 deals, an 18% drop in dollars and 20% decline in deals from the prior quarter. Click here to check out the full report >>
TOP HEADLINES
Featured Story
Microsoft developing database to diversify clinical trials
Microsoft is applying its database know-how to the problem of the lack of minority participation in clinical trials. The tech giant is turning data gathered by the National Minority Quality Forum into a searchable national archive to support the diversification of trials.
Genomics? There could be an app for that
Individualized medicine based on genomics is about to hit the masses, Wired predicts, and that could mean storing genetics data on your smart phone in the not-so-distant future.
Academics mine Twitter for research ideas
For years pharma skirted online message boards for fear of opening a Pandora's box of adverse event liabilities. But now academics are using the wealth of online medical talk to their advantage by searching for new areas of scientific investigation on message boards and Twitter.
Boehringer Ingelheim goes to Hungary for R&D software
ChemAxon has fattened its pharma business, landing a deal with German drug powerhouse Boehringer Ingelheim. Budapest-based ChemAxon announced Feb. 14 that the drugmaker plans to use its chemistry software platform in the process of ushering compounds from discovery to the clinic.
EU enters expensive race to map out brain secrets with computers
Unlocking the secrets of the brain could bring incredible economic spoils from new therapies, information technologies and artificial intelligence.
CLC bio capitalizes on surge in DNA sequencing
CLC bio wants the world to know that business is good, but the world might be more interested in why its business has taken off. The Danish provider of bioinformatics software touts today that its software sales shot up 30% in 2012 with an equal jump in its number of employees.
From Our Sister Sites
Suppliers are not only looking to buy APIs in Asia and India; they are also looking to sell them there. So hot on the heels of a deal that expanded its operations into Malaysia, Netherlands-based IMCD Group has picked up an API distributor in India.
Forget Asia and China. Another booming region for medical devices in the coming years will be the Middle East and North Africa, with expectations that the market will double within 5 years from about $1 billion annually now, TradeArabia reports.
POPULAR COMMENT THREADS